Hemlibra (emicizumab)  Solution for Injection

Summary of Product Characteristics

Patient Information Leaflet

 

Tecentriq (atezolizumab)  Concentrate for Solution for Infusion

Summary of Product Characteristics

Patient Information Leaflet

 

RoActemra (tocilizumab) Concentrate for Solution for Infusion

Summary of Product Characteristics

Patient Information Leaflet

 

RoActemra (tocilizumab) Solution for Injection in Pre-Filled Syringe

Summary of Product Characteristics

Patient Information Leaflet

 

RoActemra (tocilizumab) Solution for Injection in Pre-Filled Pen

Summary of Product Characteristics

Patient Information Leaflet

 

Alecensa (alectinib) ▼ Hard Capsules

Summary of Product Characteristics

Patient Information Leaflet

 

Adverse events for Hemlibra, Tecentriq, RoActemra and Alecensa should be reported to Roche Products Ltd. Please contact Roche drug safety centre by emailing Roche.Hemlibra, Tecentriq and RoActemra are biological medicines, Healthcare Professionals should report adverse reactions by brand name and batch number.

 

Granocyte (lenograstim) Powder and Solvent for Solution for Injection/Infusion

Summary of Product Characteristics

Patient Information Leaflet

 

Aloxi (palonosetron) Solution for Injection

Summary of Product Characteristics

Patient Information Leaflet

 

Aloxi (palonosetron) Soft Capsules

Summary of Product Characteristics

Patient Information Leaflet

 

Akynzeo (palonosetron/netupitant) ▼ Hard Capsules

Summary of Product Characteristics

Patient Information Leaflet

 

 

Antepsin (sucralfate) Oral Suspension

Summary of Product Characteristics

Patient Information Leaflet

 

Antepsin (sucralfate) Tablets

Summary of Product Characteristics

Patient Information Leaflet

 

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.  To report and adverse reaction please click here for further information.